Theravance Biopharma, Inc.
NASDAQ:TBPHBiotechnology
-$0.07 today
- Market cap
- $882.64M
- Beta
- 0.18
- P/E (TTM)
- 7.4
- EPS (TTM)
- $2.23
Volume 10.02M
Average 0.43M
TBPH Total Non-current Assets
All assets not expected to be converted to cash within one year.
Theravance Biopharma, Inc.NASDAQ: TBPH
Total Non-current Assets · Q1 FY2026 · quarter ended Mar 2026
Total non-current assets falls 71.7% from a year ago
Total non-current assets stood at $54.68M at the end of Q1 FY2026, down 71.7% from a year earlier and down 18.5% from the prior quarter. Over 3 fiscal years it compounded at -35.8% a year.
Context
- Total non-current assets amounted to 11.6% of total assets at the end of Q1 FY2026, down 44.7 pp from a year earlier.
- Total non-current assets increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current assets keeps falling in the next quarterly balance sheet after a -71.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 67.11M USD
- Year-over-year change
- -65.2%
- 4-year CAGR
- -14.4%
| Period | Period end | Total Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 67.11M | -65.2% |
| FY2024 | 2024-12-31 | 193.09M | -22.3% |
| FY2023 | 2023-12-31 | 248.46M | -2.2% |
| FY2022 | 2022-12-31 | 253.94M | +103.2% |
| FY2021 | 2021-12-31 | 124.95M | — |
Total Non-current Assets vs competitors
How TBPH compares with its peers on the latest reported figures
- Peers report in different currencies, so total non-current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -71.7% is the 8th highest of 9, against a peer median of -6.4%.
- Total non-current assets amounts to 11.6% of total assets for TBPH, versus a peer median of 7.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $502.6M USD | +33.8% | +20.0% | 49.0% | |
| Mar 2026 | €170.75M EUR | -12.5% | -3.6% | 45.9% | |
| Mar 2026 | $58.88M USD | -3.3% | -5.9% | 8.0% | |
| Mar 2026 | $54.68M USD | -71.7% | -35.8% | 11.6% | |
| Dec 2025 | $53.24M USD | -5.0% | -1.0% | 16.0% | |
| Mar 2026 | $35.59M USD | -46.6% | +69.5% | 6.7% | |
| Mar 2026 | $17.43M USD | -7.8% | +24.5% | 4.2% | |
| Mar 2026 | $4.17M USD | +22.8% | +143.3% | 1.5% | |
| Mar 2026 | $595K USD | -98.0% | +8.8% | 0.2% | |
| Peer median (excluding TBPH) | — | -6.4% | +14.4% | 7.3% | |
Competitors are the stored peer set for TBPH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 89.96M | 298.17M | 39.55M | 37.8M | 167.81M |
| Short-term Investments | 83.51M | 29.31M | 62.88M | 50.55M | 147.55M |
| Net Receivables | 57.6M | 16.79M | 17.47M | 68.44M | 95.54M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 8.56M | 7.68M | 11.6M | 4.2M | 7.56M |
| Total Current Assets | 249.87M | 353.46M | 133.54M | 161.07M | 418.46M |
| Property, Plant & Equipment (Net) | 53.35M | 52M | 45.36M | 35.77M | 30.27M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 68.37M | 0 | 0 | 0 | 14.35M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.23M | 201.94M | 203.1M | 157.32M | 22.5M |
| Total Non-current Assets | 124.95M | 253.94M | 248.46M | 193.09M | 67.11M |
| Total Assets | 374.82M | 607.4M | 382M | 354.16M | 485.57M |
| Account Payables | 3.1M | 1.55M | 1.52M | 2.24M | 2.57M |
| Short-term Debt | 17.44M | 0 | 0 | 0 | 10.95M |
| Tax Payables | 0 | 0 | 0 | 5.85M | 0 |
| Deferred Revenue | 98K | 24K | 0 | 0 | 0 |
| Other Current Liabilities | 25.15M | (24K) | 12.88M | 0 | 6.91M |
| Total Current Liabilities | 58.59M | 28.72M | 24.77M | 32.09M | 38.3M |
| Long-term Debt | 599.39M | 0 | 0 | 0 | 32.8M |
| Deferred Tax Liabilities | 240K | 0 | 0 | 0 | 85.68M |
| Deferred Revenue (Non-current) | 310K | 192K | 0 | 0 | 0 |
| Other Non-current Liabilities | 2.18M | 91.29M | 99M | 107.42M | 313K |
| Total Non-current Liabilities | 654.81M | 136.89M | 144.24M | 146.53M | 150.55M |
| Total Liabilities | 713.39M | 165.6M | 169M | 178.62M | 188.85M |
| Common Stock | 1K | 1K | 0 | 0 | 1K |
| Retained Earnings | (1.73B) | (853.91M) | (909.1M) | (965.52M) | (859.63M) |
| Accumulated OCI | (0) | (15K) | (65K) | 7K | 61K |
| Other Stockholders Equity | 0 | 0 | (0) | (0) | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | (338.57M) | 441.8M | 213M | 175.55M | 296.72M |
| Total Debt | 669.52M | 52.16M | 49.16M | 49.82M | 75.5M |
| Net Debt | 579.56M | (246.01M) | 9.61M | 12.02M | (92.31M) |
Theravance Biopharma, Inc.
NASDAQ:TBPH
Intrinsic Alpha fair value
Locked
Current Price
$17.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.